TABLE 1.
Clinical characteristics of the study population.
| Characteristic | HD | SAA | p-Value |
|---|---|---|---|
| Age | — | — | — |
| Medium | 30.33 | 29.73 | 0.8924 |
| Range | 17–54 | 20–64 | — |
| Gender | — | — | 0.8367 |
| Female | 7 | 6 | — |
| Male | 8 | 8 | — |
| WBC, 109/L | — | — | — |
| Average | — | 1.71 | — |
| Range | — | 0.75–2.87 | — |
| RBC, 1012/L | — | — | — |
| Average | — | 2.03 | — |
| Range | — | 1.27–2.87 | — |
| Hemoglobin, g/L | — | — | — |
| Average | — | 62.31 | — |
| Range | — | 38–88 | — |
| PLT, 1012/L | — | — | |
| Average | — | 16.36 | — |
| Range | — | 0–46 | — |
| Patient type | — | — | — |
| Newly diagnosed | — | 8 | — |
| Remission | — | 0 | — |
| Non-remission | — | 6 | — |
| Drug | — | — | |
| Anti-infective agents | — | 7 | — |
| Androgen | — | 2 | — |
| Ciclosporin | — | 5 | — |
| Eltrombopag | — | 3 | — |
| ATG | — | 1 | — |
| G-CSF | — | 2 | — |
Note. HD, healthy donors; SAA, severe aplastic anemia; Remission, the patients who had been diagnosed and responded to the treatment; Non-remission, patients who had been diagnosed but did not respond to the treatment; ATG, antithymic globulin; G-CSF, granulocyte colony-stimulating factor; WBC, white blood cell; RBC, red blood cell; PLT, platelet count.